Quest Diagnostics ( (DGX) ) has provided an update.
On March 19, 2025, Quest Diagnostics hosted its Investor Day, where the leadership team outlined strategies for sustainable growth and long-term shareholder value. The company reaffirmed its 2025 guidance and provided a long-term outlook, anticipating revenue growth at a 4-5% CAGR and adjusted EPS growth at a 7-9% CAGR beyond 2025. Key initiatives include expanding market access, advancing diagnostics, and modernizing IT systems to enhance productivity and customer experiences. Despite a weather-related revenue headwind in Q1 2025, Quest remains focused on strategic partnerships and acquisitions to drive growth.
More about Quest Diagnostics
Quest Diagnostics is a leading provider of diagnostic information services, offering insights derived from laboratory testing to empower individuals, physicians, and organizations in improving health outcomes. The company serves one in three adult Americans and half the physicians and hospitals in the United States, leveraging one of the world’s largest databases of de-identified clinical lab results.
YTD Price Performance: 14.87%
Average Trading Volume: 1,053,218
Technical Sentiment Consensus Rating: Sell
Current Market Cap: $19.14B
Learn more about DGX stock on TipRanks’ Stock Analysis page.
Trending Articles:
Questions or Comments about the article? Write to editor@tipranks.com